Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol 24-hour lung function crossover study in COPD
NL-OMON37551Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: FEV1 AUC0-24h response. Started May 2012; status: active, not recruiting.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON37551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37551.